Abstract
Treatment with SGLT2i was associated with a decreased risk of new-onset inflammatory skin diseases including vitiligo, acne vulgaris, rosacea, and urticaria in diabetic patients. Prospective studies and clinical trials are warranted to validate the safety and efficacy of SGLT2i in patients with diabetes and concomitant inflammatory skin diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
